Tirzepatide
Tirzepatide is Eli Lilly’s dual GLP-1/GIP agonist — sold as Mounjaro for type 2 diabetes and Zepbound for weight management — the current efficacy benchmark in the weight-loss category.
- Eli Lilly’s dual agonist: Mounjaro and Zepbound
- SURMOUNT trials set the current efficacy benchmark
- LillyDirect vials anchor the cash-pay channel
- Shortage resolved late 2024; compounding moved to the patient-specific pathway
Why tirzepatide moved the market
The SURMOUNT trials showed average weight reduction beyond what single-agonist GLP-1s had achieved, making Zepbound the request patients arrive with. Lilly leaned into cash-pay access earlier than its rival — single-dose vials through its LillyDirect self-pay channel at prices meaningfully below auto-injector list — a move that shaped how DTC programs structure tirzepatide offerings.
Program considerations
Tirzepatide programs run the standard GLP-1 playbook — clinician evaluation, molecule-specific titration, refill gating on check-ins — with two specifics: the vial-based cash channel means patient instruction on syringe draw rather than auto-injectors for some products, and demand routinely arrives pre-anchored on Zepbound specifically, which makes clinician-led therapy selection (rather than order-taking) both the compliant and the clinically right pattern. Its shortage ended in late 2024, moving compounded tirzepatide to the patient-specific pathway.
Mounjaro vs Zepbound
| Brand | Indication | Cash channel | Notes |
|---|---|---|---|
| Mounjaro | Type 2 diabetes | Coverage-led | Diabetes formularies; off-label weight use at clinician discretion |
| Zepbound | Weight management + obstructive sleep apnea | LillyDirect single-dose vials | The on-label weight product; OSA indication (Dec 2024) strengthened the coverage story |
Why it resets benchmarks
SURMOUNT’s roughly 21% average weight reduction at the top dose made Zepbound the arrival request — patients come in asking for it by name. The OSA indication broadened the clinical case and gave coverage conversations a second anchor. For programs, the operational specifics are the vial-based cash channel (syringe-draw instruction rather than auto-injectors) and the discipline of keeping therapy selection a clinician decision rather than an order form.
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
What is the difference between Mounjaro and Zepbound?
Same molecule, different indications: Mounjaro for type 2 diabetes, Zepbound for weight management — programs should align with the on-label product.
Is compounded tirzepatide available?
Through the patient-specific pathway — prescriptions reflecting documented individual clinical needs. The broad shortage-era window closed when the FDA declared the shortage resolved in late 2024.
Why do patients specifically request Zepbound?
Trial results and press coverage made it the perceived strongest option — which is exactly why therapy selection must remain a clinician’s decision, not a menu order.